TY -的T1 -实现专业Teleneurology门诊病人和病人的经验在一个学术机构在四年内(Plen01.004) JF -神经学乔-神经学六世- 92 - 15补充S首页P - Plen01.004 AU -罗斯琳赛盟-詹姆斯希伯来文名字AU -罗伯特Bermel AU -劳伦麦卡特盟Zubair Ahmed AU -哈罗德Goforth盟-尼尔·契连盟詹妮弗Kriegler AU - Emad Estemalik AU -马修·斯坦顿盟-彼得·拉斯穆森AU -休伯特费尔南德斯盟Imad Najm盟玛丽莎麦克金尼Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_Supplement/Plen01.004.abstract N2 -目的:描述实施专业Teleneurology门诊病人和病人的经验在学术机构四年。背景:Teleneurology首页已经被描述为急性中风但其门诊使用是有限的。特别是,很少有研究在神经学评估个人使用视频会议平台。首页国内虚拟访问有可能改善病人的神经专科护理,否则经常需要旅行。旅行可能是困难的病人由于费用和残疾。需要提高访问质量的神经护理。设计/方法:所有成年患者完成虚拟神经后续访问从一个三级医疗机构在一个四年了。虚拟访问由个人智能手机或电脑通过视频会议与提供者。病人被要求给他们的整体经验与访问和提供者(5点量表)。旅行的距离计算机构使用病人的家庭住址。结果:3958例患者5646个虚拟访问四年期间完成。 Virtual visits were completed in all outpatient subspecialities with breakdown as follows: Headache 21.4%, Epilepsy 19.1%, Spine 15.7%, Movement 10.8%, Psychiatry 6.4%, Autonomic 5.7%, Cerebrovascular 4.8%, Cognitive 3.6%, and the remainder being <3.5%. 29.8% of patients were local (<50 miles), 25.9% were near regional (50–150 miles), 21.6% were far regional (151–270 miles), and 23.1% were remote (>270 miles). Across the 5646 visits, 1,418,688 miles of travel was prevented. Number of virtual visits increased from 30 visits year 1 to 4514 year 4. 25.1% of patients completed multiple virtual visits. On average, patients rated their overall experience with the virtual visit 4.7/5 and rated their provider 4.9/5.Conclusions: This study demonstrates the feasibility of implementing subspecialty teleneurology services and high patient ratings for these services. Future efforts should focus on demonstrating value for patients and the health care system.Disclosure: Dr. Ross has nothing to disclose. Dr. Bena has nothing to disclose. Dr. Bermel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Genentech, Novartis, Roche. Dr. Bermel has received research support from Biogen, Genentech, Roche. Dr. McCarter has nothing to disclose. Dr. Ahmed has nothing to disclose. Dr. Goforth has nothing to disclose. Dr. Cherian has nothing to disclose. Dr. Kriegler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with DynaMed Plus. Dr. Kriegler has received research support from Allergan and Amgen. Dr. Estemalik has nothing to disclose. Dr. Stanton has nothing to disclose. Dr. Rasmussen has nothing to disclose. Dr. Fernandez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prime Education Inc. International Parkinson and Movement Disorders Society, Carling Communications, Medscape, Vindico, AbbVie, Biogen, Blackthorn, Inventiv, Kyowa Hakko Kirin, Medscape, Voyager, Sunovion, and Pfizer Pharmaceuticals. Dr. Fernandez has received royalty, license fees, or contractual rights payments from Demos Publishing, Cambridge University Press. Dr. Fernandez has received research support from Abbvie, Biotie/Acorda Therapeutics, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, Sunovion. Dr. Najm has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai. Dr. McGinley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme and Genentech. ER -